Parent company $ALMEX is soaring. Why?
Its sub $RDAR just eliminated debt from last year’s acquisition.
Is $RDAR next? Clean books. Acquisition catalyst (AmeriCrew) brewing. Smart money already buying the parent.
$RDAR
Telvantis announces $1 million share buyback program!
Our Board of Directors has approved a program to repurchase up to $1M of common stock. This marks a strong signal of confidence in our valuation and long-term strategy.
Full details here: https://t.co/Ec9p5lVjpE
$RDAR DD (Part 1)
•$5M market cap
•$32M revenue across Feb-March
•$62M in Assets (10-K)
•Audit underway
•Big name clients including AT&T $T, Verizon $VZ
•Acquisitions, evaluating targets
•Share buyback
•NYSE Floor interview 4/30
•Multiple analyst reports issued to the parent company Mexedia S.p.A which is listed on the Euronext Paris exchange (EPA: ALMEX)
•Acquired 100% ownership of Mexedia Inc and Mexedia DAC which combined reported $349M in revenues in 2023. (Post merger $32M in revenue across Feb-March in 2025 mentioned in a recent PR by RDAR)
•Settled all outstanding convertible debt
•45M working capital facility
•No R/S Company mentioned numerous times that they will not do a reverse split in PR’s and filings
•Strong management team with serious track records
•Plans to uplist
Also here are links to 2 analyst reports that were issued to their parent company Mexedia S.p.A listed on the Euronext Paris exchange (ALMEX:PA)
GBC AG analyst report: https://t.co/8KOyyv0f6A
Integrae SIM analyst report: https://t.co/M1QDr2U4cw
GBC AG is a investment bank in Germany https://t.co/MpPfDUG7cW
Integrae SIM is a financial advisory firm in Italy https://t.co/6UNSWXTwS1
$RDAR websites:
Telvantis https://t.co/sagRvGzZXO
Mexedia https://t.co/9Jodst839q
One of the best plays in the OTC imo, I will be posting a lot more DD on this one
$RDAR
Massive opportunity for 1,000% to 10,000% gains for me.
$32 M revenue just in last 2 months. Current Marker Cap ONLY 5M.
Do your math.
https://t.co/tCOyi5DVDq
$TWOH $FITY $HMBL
$RDAR - Telvantis Confirms No Reverse Stock Split & Advances Uplisting Strategy
Telvantis remains committed to long-term growth, shareholder value, and securing a national market listing. No RS is planned, and multiple strategic pathways—including a potential SPAC merger—are under evaluation.
CEO Daniel Contreras:
"We believe Telvantis is significantly undervalued. Our focus remains on disciplined execution and financial strength as we explore the best path to uplisting.”
Telvantis has also initiated its PCAOB audit, a key milestone in strengthening financial transparency and positioning for institutional investment.
Read the full press release: https://t.co/kURo1a6Pks
#Telvantis #InvestorUpdate #NASDAQJourney #Uplisting #FinancialGrowth
Virogentics IPF Immune® TV and CTV commercials are anticipated to begin airing on Friday and to carry through into 2024. We thank @trndysocial, @TikiBarber, and our many supporters.
We wish you and your families happy holidays and a happy new year!
https://t.co/6tNCZkSFDZ